Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Hose

Showing results (151-160 of 189) with videos related to

Pageof 19
Sort By:
Blood|June 25, 2010
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patientsAnnemiek Broyl, Dirk Hose, Henk Lokhorst, et al.
Nature Communications|November 30, 2021
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomicsStephan M Tirier, Jan-Philipp Mallm, Simon Steiger, et al.
European Journal of Haematology|November 11, 2025
Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 TrialTim Richardson, Elias Mai, Ekaterina Menis, et al.
Blood Cancer Journal|August 29, 2019
Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myelomaMaximilian Merz, Thomas Hielscher, Elias Karl Mai, et al.
Blood Cancer Journal|January 31, 2019
Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patientsKatharina Kriegsmann, Marc-Andrea Baertsch, Mohamed H S Awwad, et al.
The American Journal of Pathology|June 16, 2017
Osteocyte Regulation of Receptor Activator of NF-κB Ligand/Osteoprotegerin in a Sheep Model of OsteoporosisThaqif El Khassawna, Felix Merboth, Deeksha Malhan, et al.
Leukemia|July 1, 2018
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myelomaElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Blood|January 28, 2009
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myelomaDirk Hose, Thierry Rème, Tobias Meissner, et al.
Haematologica|August 20, 2016
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
Cancer Immunology Research|July 16, 2020
CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti-PD-L1 TreatmentValentina Volpin, Tillmann Michels, Antonio Sorrentino, et al.
Pageof 19

Showing results (151-160 of 189) with videos related to

Sort By:
Pageof 19
Blood|June 25, 2010
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patientsAnnemiek Broyl, Dirk Hose, Henk Lokhorst, et al.
Nature Communications|November 30, 2021
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomicsStephan M Tirier, Jan-Philipp Mallm, Simon Steiger, et al.
European Journal of Haematology|November 11, 2025
Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 TrialTim Richardson, Elias Mai, Ekaterina Menis, et al.
Blood Cancer Journal|August 29, 2019
Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myelomaMaximilian Merz, Thomas Hielscher, Elias Karl Mai, et al.
Blood Cancer Journal|January 31, 2019
Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patientsKatharina Kriegsmann, Marc-Andrea Baertsch, Mohamed H S Awwad, et al.
The American Journal of Pathology|June 16, 2017
Osteocyte Regulation of Receptor Activator of NF-κB Ligand/Osteoprotegerin in a Sheep Model of OsteoporosisThaqif El Khassawna, Felix Merboth, Deeksha Malhan, et al.
Leukemia|July 1, 2018
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myelomaElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Blood|January 28, 2009
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myelomaDirk Hose, Thierry Rème, Tobias Meissner, et al.
Haematologica|August 20, 2016
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.
Cancer Immunology Research|July 16, 2020
CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti-PD-L1 TreatmentValentina Volpin, Tillmann Michels, Antonio Sorrentino, et al.
Pageof 19